Medical Information
Norway
 

Den medisinske informasjonen på dette nettstedet er kun beregnet for helsepersonell i Norge.

Vennligst merk at videre innhold på denne nettsiden vil bli presentert på engelsk.

For å gi deg relevant innhold, trenger vi å vite mer om deg.

Velg kategorien som best beskriver deg.

Informasjonen på dette nettstedet er kun beregnet for helsepersonell i Norge. Vil du fortsette?

Please enter product name and question keywords in English.

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.
Not a healthcare professional? Go to the patient or caregiver website.

European Medicines Agency (EMA) has issued a Conditional Marketing Authorisation (CMA) to permit use of the product COMIRNATY COVID-19 mRNA Vaccine for active immunisation to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 12 years of age and older. During the initial pandemic stage, COMIRNATY COVID-19 mRNA Vaccine may also be distributed with the packaging with the name Pfizer-BioNTech COVID-19 Vaccine.

COMIRNATY (COVID-19 mRNA vaccine)

Please enter product name and question keywords in English.

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

COMIRNATY Quick Finder

The full Summary of Product Characteristics for COMIRNATY is available here.



Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event